JPMorgan analyst James Gordon raised the firm’s price target on Argenx to EUR 480 from EUR 470 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARGX:
- argenx to Present at Upcoming Investor Conferences
- Jefferies pharma/biopharma analysts hold analyst/industry conference call
- Cowen biotech/pharma analysts hold an analyst/industry conference call
- Argenx price target raised to $440 from $425 at H.C. Wainwright
- Piper Sandler remains a buyer of Argenx after Q3 beat